Obuhangire bwa Kymera Therapeutics (KYMR) bwa Sikaati
AI forecast: KYMR
AI ebandika ekiruho ky'obusobozi bw'omubere gw'ekiseera ekiddako, ekigero ky'omubere gw'ebirungi, n'ekigero ky'omubere gw'omwezi. Okuhinduka kuhakirizwa hakurikira obusobozi bwa nyuma. Bino ni obuhangire bw'obusobozi, si obuhangire bw'okuhanga.
Ebiharwa by'omwaka guhera mu myezi 6 eyita
Premium erikahyora ebyifujiraho by'AI eby'omutengo mu nsi y'omunzi omu, wiiki emu n'omwaka omu ku kizigirwa kino n'ebirala byonna.
Unlock Premium🔒 Ekihugho ky'obuhangire bw'obusobozi
Ekihugho ky'obuhangire bw'obusobozi — buli kihuugho ky'omubere gya nyuma hafi n'obusobozi bwa nyakuri — ni ekigero cya Premium.
Unlock PremiumEbikwata ku Kitongole Kino
Kymera Therapeutics, Inc. operates as a biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation machinery. Kymera Therapeutics serves customers in Massachusetts.
